SCHEMBL4939682

SCHEMBL4939682

Cc1ccc(-n2c(O)nnc2-c2ccc(O)cc2O)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 3/20 0.48
TSHR P16473 3/20 0.41
LMNA P02545 3/20 0.41
ALDH1A1 P00352 3/20 0.41
POLB P06746 2/20 0.40
ALOX15 P16050 2/20 0.39
MAPK1 P28482 1/20 0.39
KDM4E B2RXH2 4/20 0.38
MAPT P10636 3/20 0.38
HTT P42858 1/20 0.38
GAA P10253 1/20 0.38
MAOA P21397 1/20 0.38
MAOB P27338 1/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
ALPG P10696 1/20 0.38
HSP90AA1 P07900 2/20 0.37
ESR2 Q92731 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.36
TDP1 Q9NUW8 2/20 0.36
HPGD P15428 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4938798 0.86 MAOA (0.39) ESR1TSHRLMNAALDH1A1MAPK1
SCHEMBL4941283 0.85 HSP90AA1 (0.41) ESR1TSHRLMNAALDH1A1ALOX15
SCHEMBL931765 0.85 ESR1 (0.46) ESR1TSHRLMNAALDH1A1POLB
SCHEMBL4940434 0.84 ACHE (0.41) ESR1POLBGAAMAOBHSP90AA1
SCHEMBL27119240 0.81 HSP90AA1 (0.40) ESR1TSHRLMNAALDH1A1POLB
SCHEMBL501144 0.80 ESR1 (0.42) ESR1TSHRLMNAALDH1A1POLB
SCHEMBL4940666 0.80 MAPT (0.43) LMNAALDH1A1POLBMAPTHTT
SCHEMBL4933396 0.77 ESR1 (0.50) ESR1HSP90AA1ESR2
SCHEMBL4933212 0.77 ESR1 (0.50) ESR1TSHRLMNAALDH1A1MAPT
SCHEMBL4939706 0.76 HSP90AA1 (0.41) ESR1MAPTHSP90AA1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080182857-A1 Triazole Derivatives MERCK PATENT GMBH (DE) 2008-07-31 US claimed
EP-1853570-A2 HSP90-INHIBITING TRIAZOLE DERIVATIVES Merck Patent GmbH (DE) 2007-11-14 EP claimed
WO-2006087077-A2 HSP90-INHIBITING TRIAZOLE DERIVATIVES MERCK PATENT GMBH (DE) 2006-08-24 WO claimed
US-8618285-B2 Triazole derivatives MERCK PATENT GMBH (DE) 2013-12-31 US disclosed
EP-1853570-B1 HSP90-INHIBITING TRIAZOLE DERIVATIVES MERCK PATENT GMBH (DE) 2012-10-24 EP disclosed
US-20080182857-A1 Triazole Derivatives MERCK PATENT GMBH (DE) 2008-07-31 US disclosed
EP-1853570-A2 HSP90-INHIBITING TRIAZOLE DERIVATIVES Merck Patent GmbH (DE) 2007-11-14 EP disclosed
WO-2006087077-A2 HSP90-INHIBITING TRIAZOLE DERIVATIVES MERCK PATENT GMBH (DE) 2006-08-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080182857-A1 Triazole Derivatives HSP90AB1, HSP90AA1, HSP90B1 ESR1 2460/4885TSHR 1164/4885LMNA 3962/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.